Multi-site, randomized, double-blind, multi-arm historical control, comparative trial of the safety and efficacy of hydroxychloroquine and the combination of hydroxychloroquine and famotidine for treatment of moderate to severe COVID-19 disease in hospital
Award Notice Posted
Not the latest version. See the latest special notice from .
- Solicitation number
- 75A50120C00078
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Awarded
- to Alchem Laboratories Corporation
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50120C00078 Federal contract award
Notice details come from SAM.gov. Updated .
About this opportunity
This Award Notice from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response provides $20,747,018 to ALCHEM LABORATORIES CORP to rapidly implement a multi-site, randomized, double-blind study comparing the safety and efficacy of hydroxychloroquine alone and in combination with famotidine for the treatment of moderate to severe COVID-19 in hospitalized adults over an unspecified period. The study will evaluate standard of care combined with hydroxychloroquine or the combination of hydroxychloroquine and high-dose intravenous famotidine against standard of care alone.
Notice text
The objective of this contract is rapidly implement a multi-site, randomized, double-blind, multi-arm historical control, comparative trial of the safety and efficacy of Hydroxychloroquine and the combination of Hydroxychloroquine and Famotidine for the treatment of moderate to severe COVID-19 disease in hospitalized adults. The study will help evaluate the clinical efficacy of COVID-19 treatments consisting of standard of care (SOC) combined with pharmaceutical antiviral management using Hydroxychloroquine or SOC or SOL combine with Hydroxychloroquine and high-dose intravenous famotidine in hospitalized patients meeting nucleic acid diagnostic and radiologic criteria for COVID-19 disease. Additional dose-ranging or therapeutic strategies including additional therapeutic compounds, as well as clinical sample testing, to improve COVID-19 treatments are also proposed.
Awarded contract 75A50120C00078 to ALCHEM LABORATORIES CORP for 20747018.00 on 2020-04-14.
Notice history
7 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity